Search

Pharmacy and pharmaceutical sciences embrace a series of different disciplines. Pharmacy practice has been defined as "the scientific discipline that studies the different aspects of the practice of pharmacy and its impact on health care systems, medicine use, and patient care". Thus, pharmacy practice studies embrace both clinical pharmacy and social pharmacy elements. Like any other scientific discipline, clinical and social pharmacy practice disseminates research findings using scientific journals. Clinical pharmacy and social pharmacy journal editors have a role in promoting the discipline by enhancing the quality of the articles published. As has occurred in other health care areas (i.e., medicine and nursing), a group of clinical and social pharmacy practice journal editors gathered in Granada, Spain to discuss how journals could contribute to strengthening pharmacy practice as a discipline. The result of that meeting was compiled in these Granada Statements, which comprise 18 recommendations gathered into six topics: the appropriate use of terminology, impactful abstracts, the required peer reviews, journal scattering, more effective and wiser use of journal and article performance metrics, and authors' selection of the most appropriate pharmacy practice journal to submit their work. [ABSTRACT FROM AUTHOR]

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Résumé: Avec la pandémie de SARS-CoV-2, dans notre établissement, les lits de salle de surveillance post-interventionnelle du bloc opératoire ont été transformés en lits de réanimation non-COVID. Le service de pharmacie a accompagné les équipes au cours des trois périodes, avec la mise en place d'un circuit du médicament adapté : création d'une armoire de dotation, fréquence d'approvisionnement, dispensation nominative et présence pharmaceutique. Objectifs : évaluer l'organisation pharmaceutique mise en place, la satisfaction des équipes infirmiers et recueillir des axes d'amélioration. Méthode : un questionnaire a été remis aux infirmiers ayant travaillé dans cette unité. Résultats : au total, 155 patients, soit une analyse de 111 prescriptions, ont été pris en charge sur 126 jours d'ouverture de cette unité. L'ensemble des infirmiers ayant participé aux trois périodes ainsi que le cadre de santé ont complété le questionnaire, soit 21 réponses. L'étape ressentie comme la plus difficile est la prescription (48 %) liée au support papier utilisé. La présence pharmaceutique a été appréciée à 90 %, notamment pour des demandes d'approvisionnement d'un médicament (95 %), ou d'information sur un médicament (58 %). Il est souhaité (90 %) que cette présence soit renouvelée en cas de réouverture de l'unité. Une amélioration de la satisfaction est constatée à chaque période. Conclusion : en cas de nouvelle vague, il a été décidé de poursuivre le détachement d'un pharmacien pour sécuriser le fonctionnement de ce type d'unité, notamment par l'analyse quotidienne des prescriptions avec les médecins et par l'interaction avec les infirmiers pour le bon usage du médicament. During the SARS CoV-2 pandemia and at three separate time period, our institution chose to turn the post interventional surveillance room of the operating room into a non-COVID intensive care unit. The chosen workflow included that the pharmacy team provided support to the medical team and was instrumental to implement an adapted drug circuit, including the creation of a supply cabinet, a specific frequency of its supply, a nominative dispensation and the presence of a pharmacist. Objectives : The study aims to evaluate the proposed pharmaceutical organization workflow, the satisfaction of the nursing team and to collect their expert feedback for improvement. Method : A satisfaction survey questionnaire was set up and given to the nurses who worked in this temporary unit. Results : A total of 155 patients, i.e. an analysis of 111 prescriptions, were treated during the 126 days during which the unit was running. All the nurses who participated to the three time periods and the health care manager completed the questionnaire, i.e. 21 responses. The step that was felt to be the most difficult was prescribing (48%) due to the paper medium used. The presence of a pharmacist in the medical unit was appreciated by 90% of the survey respondents, particularly for requests on the supply of a drug (95%), or on drug information (58%). 90% of the respondents were hoping that this experience would be renewed if the unit opens again. An increase of the satisfaction due to the pharmaceutical presence is reported in each successive period. Conclusion : In case of an eventual new epidemic wave, it was decided to continue to assign a pharmacist to the non-COVID intensive care unit, in order to protect the unit performance. The survey revealed that two key factor are instrumental to this success, a daily analysis of prescriptions with the physicians and the on-site interaction with the nurses for the promotion of the right use of medications. [ABSTRACT FROM AUTHOR]

Résumé: Après un premier article portant sur l'aspect théorique [1], place à la partie opérationnelle de la gestion de projet illustrée par deux solutions organisationnelles (SO) publiées en 2019 par l'Agence nationale d'appui à la performance des établissements de santé et médico-sociaux (ANAP). Du cadrage de projet jusqu'à sa clôture en passant par la mise en œuvre, cet article propose une méthodologie illustrée par un cas concret que les pharmaciens hospitaliers pourront appliquer pour mener leurs projets. Elle s'accompagne de nombreux outils tels qu'un tableau de Kanban, un plan de communication, une note de cadrage. Ces éléments primordiaux dans la pratique quotidienne du pharmacien hospitalier, pourraient à moyen terme être connus et acquis dès notre formation initiale pour répondre aux nouveaux enjeux du métier de pharmacien hospitalier. Following our first paper on theoretical issues of project management [1], we address in this one the practical part, illustrated by two organizational solutions (OS) published in 2019 by the Agence Nationale d'Appui à la Performance des établissements de santé et médico-sociaux (ANAP). From the definition of the project to its implementation and completion, this article provides a methodology illustrated by a concrete case that hospital pharmacists could apply to their own projects. It also provides many tools such as a Kanban board, a communication plan and a scoping note. These elements are already essential in the daily practice of the hospital pharmacist and we suggest that this should be acquired during our initial training to meet the new challenges of the hospital pharmacist's profession. [ABSTRACT FROM AUTHOR]

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Résumé: Le dernier congrès de l'ISPOR Europe (International society for pharmacoeconomics and outcomes research) s'est tenu à Copenhague du 2 au 6 novembre 2019. Un groupe de pharmaciens, médecins et économistes en santé en synergie avec un groupe d'étudiants en master 2 de médico-économie présents à Copenhague, ont choisi de vous en restituer les messages forts. Cette synergie de groupe vise à développer « l'approche de la médico-économie sous toutes ses facettes ». Dans cet article, les auteurs évoquent les questions issues des différentes sessions et/ou posters, notamment l'évaluation des produits de santé : comment accélérer l'accès au marché des traitements tout en garantissant la pertinence clinique et la maîtrise des dépenses ? The last congress of ISPOR Europe (International society for pharmacoeconomics and outcomes research) was held in Copenhagen from 2 to 6 November 2019. A group of pharmacists, physicians and health economists in synergy with a group of students in Master 2 of medico-economics attending the conference have chosen to share some of the highlights. This group synergy aims to develop "the medico-economic approach in all its facets". In this paper, the authors discussed the following questions from the different sessions and/or posters, in particular the evaluation of health products: how to accelerate access to the treatment market while ensuring clinical relevance and control of spending? [ABSTRACT FROM AUTHOR]

Résumé: Le congrès européen 2018 de l'ISPOR Europe (International society for pharmacoeconomics and outcomes research) s'est tenu à Barcelone du 10 au 14 novembre 2018. Lors de ce congrès, ont été débattus les sujets d'actualités qui agitent le monde de la santé et bien au-delà : la santé numérique. Un groupe de pharmaciens, médecins et économistes en santé présents à Barcelone, a choisi de vous en restituer les messages forts. Dans cet article, les auteurs évoquent les questions issues des différentes sessions et/ou posters : après la libre circulation des personnes, des biens et services, l'Europe et le reste du monde sont confrontés à un nouveau mouvement : la « libre circulation des données », ce changement est-il une opportunité ou une menace pour la vie privée des patients ? La santé numérique peut-elle être source d'inégalités sociales ? Les métiers de la santé sont-ils menacés par l'intelligence artificielle (IA) notamment les économistes en santé ? Quelle sécurité dans l'utilisation des applications mobiles (Apps) et objets connectés (OC) ? Autant de questions discutées dans cet article pour l'enthousiasme ou le scepticisme qu'elles suscitent. The 2018 european congress of the ISPOR Europe (International society for pharmacoeconomics and outcomes research) was held in Barcelona from 10 to 14 November 2018. During the congress, the news topics that are stirring the world of health and far beyond were discussed: digital health. A group of pharmacists, physicians and health economists attended the conference and reported some of the highlights. In this paper, the authors discussed the following questions from the different sessions and/or posters. After the free movement of people, goods and services, Europe and the rest of the world should deal with a new trends: the "free flow of data". Is this change an opportunity or a threat to the privacy of patients? Can digital health be a source of social inequality? Are health professions threatened by artificial intelligence (AI) especially health economists? What security in the use of mobile applications (Apps) and connected objects (OC)? These are issues of both enthusiasm and concern that will be discussed according to the following plan. [ABSTRACT FROM AUTHOR]

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Résumé: Les antiagrégants plaquettaires (AAP) exposent à des risques d'hémorragie gastro-intestinale importants. Les inhibiteurs de la pompe à protons (IPP) semblent prévenir ce risque mais leur prise au long cours peut entraîner des effets indésirables et des coûts importants. L'identification des patients devant bénéficier d'une prévention est donc nécessaire. Il existe différentes recommandations quant à cette utilisation des IPP. L'objectif principal de cette étude était d'évaluer le respect des recommandations de gastro-protection par IPP pour les patients traités par AAP au centre hospitalo-universitaire de Rennes. L'objectif secondaire était d'étudier les facteurs associés aux prescriptions d'IPP. Pour tous les patients sous AAP le 05 juin 2019, la co-prescription d'un IPP a été recueillie, ainsi que des facteurs de risque connus d'hémorragie. Le respect des recommandations a été analysé ainsi que les facteurs associés à la prescription d'IPP. Parmi les 287 patients inclus, 126 (43,9 %) sont sous IPP. Lorsqu'un IPP est recommandé, il est bien prescrit dans 80 % des cas. Parmi les patients présentant d'autres facteurs de risque non couverts par les recommandations, 56,3 % n'ont pas d'IPP. Aucune justification n'est retrouvée pour 21 % des prescriptions d'IPP. Tous les patients ayant des antécédents d'hémorragie digestive ou un reflux gastro-œsophagien sont sous IPP. Les autres facteurs significativement associés à la prescription d'IPP sont la double anti-agrégation plaquettaire (OR : 4,71 [2,14-10,34]) et l'anticoagulation (OR : 2,92 [1,29-6,63]). Les critères définissant les sujets à risque mériteraient d'être précisés dans les recommandations nationales et les professionnels de santé sensibilisés à évaluer le rapport bénéfice risque des IPP. Antiplatelet agents expose to an important risk of gastro-intestinal bleeding. Proton pump inhibitors (PPI) seem to prevent this risk but their long-term use can be responsible of adverse effects and represents important costs. Identifying patients who would beneficiate of a PPI prevention is necessary. Different guidelines exist regarding this preventive use. The primary objective of this study was to evaluate the agreement of PPI prescriptions with the guidelines for patients treated with antiplatelet agents in Rennes' University hospital. The secondary objective was to analyze factors associated with PPI prescription. For all patients with an antiplatelet prescription on 05/06/2019, we searched for co-prescription of a PPI as well as other known bleeding risk factors. We analyzed the agreement with the guidelines as well as the factors associated with PPI prescription. Among the 287 patients included, 126 (43.9%) were treated with a PPI. National guidelines were well respected (>80%) when a PPI was recommended. However, 56.3% of patients presenting other bleeding risk factors, not mentioned in these guidelines, were not protected by a PPI. We found no justification for 21% of all PPI prescriptions. All patients with a history of gastro-intestinal bleeding or gastro-esophageal reflux disease were protected by a PPI. Other factors significantly associated with PPI prescription were dual antiplatelet therapy (OR: 4.71 [2.14-10.34]) and anticoagulation (OR: 2.92 [1.29-6.63]). The criteria which define patients at risk should be better specified in national guidelines. Health professionals should also be sensitized to evaluate the benefit risk ratio of PPI prescription. [ABSTRACT FROM AUTHOR]

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Résumé: Objectifs. Résumer la littérature relative aux rôles du pharmacien en dermatologie-allergologie, présenter un profil succinct de ces deux secteurs et développer une offre de soins pharmaceutiques cohérente en dermatologie-allergologie au Centre hospitalier universitaire (CHU) Sainte-Justine. Méthodes. Il s'agit d'une étude descriptive constituée d'une revue de littérature des articles portant sur le rôle du pharmacien en dermatologie-allergologie, d'une description sommaire des secteurs de la dermatologie et de l'allergologie, ainsi que de la mise à jour de l'offre de soins pharmaceutiques dans ces secteurs. Résultats. Un total de 35 articles (16 en dermatologie et 19 en allergologie) ont été inclus dans la revue de littérature. La majorité de ces articles était de faible qualité et décrivait les activités pharmaceutiques sans en mesurer l'impact. Les activités pharmaceutiques principalement rapportées par la littérature étaient la réalisation de conseils aux patients (articles de dermatologie) et la documentation des interventions effectuées (articles d'allergologie). En 2017-2018, les secteurs de la dermatologie et de l'allergologie ont effectué environ 14 000 et 5 000 consultations médicales de façon respective. L'offre de soins pharmaceutiques a été mise à jour en fonction de 21 activités pharmaceutiques, permettant d'identifier la pertinence d'un pharmacien répondant en dermatologie-allergologie. Conclusion. Il existe peu de données sur les rôles et les retombées de l'activité pharmaceutique en dermatologie-allergologie. Cet article présente une démarche originale incluant une revue de littérature (35 articles), un profil succinct des secteurs et une réflexion entourant les activités pharmaceutiques d'un pharmacien répondant en dermatologie-allergologie au sein d'un centre hospitalier universitaire mère-enfant. Objectives. Summarize the literature on the pharmacist's role in dermatology-allergology, present a brief description of these two sectors and develop a pharmaceutical care offer in dermatology-allergology in a mother-child teaching hospital center. Methods. This article is a descriptive study consisting of a literature review on the pharmacist's role in dermatology-allergology, a brief description of the dermatology and allergology sectors and an optimization of the pharmaceutical care in these sectors. Results. A total of 35 articles (16 in dermatology and 19 in allergology) were included in the literature review. The majority of these articles were of poor quality and described the pharmaceutical activities without measuring their impact. The pharmaceutical activities mainly reported in the literature were the advices to patients (dermatology articles) and the documentation of the pharmaceutical interventions (allergy articles). In 2017-2018, the dermatology and allergology sectors performed approximately 14,000 and 5,000 medical consultations respectively. The pharmaceutical care offer has been updated, allowing us to identify the relevance of a responding pharmacist in dermatology-allergology. Conclusion. There is few data on the roles and outcomes of the dermatology-allergology pharmaceutical activities. This article presents an original approach including a literature review (35 articles), a brief profile of the sectors and a reflection on the pharmaceutical activities of a dermatology-allergology pharmacist in a mother-child teaching hospital center. [ABSTRACT FROM AUTHOR]

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal de Pharmacie Clinique is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)